Evidence map›Paper›PMID 36970719›Full record

ArticleCancer research communications2022

Loss of Dok-3 in Non-tumor Cells Induces Malignant Transformation of Benign Epithelial Tumor Cells of the Intestine.

Sumimasa Arimura, Akane Inoue-Yamauchi, Kotoe Katayama, Tatsuo Kanno, Hiroki Jozawa, Seiya Imoto, Yuji Yamanashi

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sumimasa Arimura *Division of Genetics, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7676-4689
Akane Inoue-Yamauchi *Division of Genetics, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-0260-8162
Kotoe KatayamaLaboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-3966-1231
Tatsuo KannoDivision of Genetics, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-4647-575X
Hiroki JozawaDivision of Genetics, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-2449-6533
Seiya ImotoLaboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-2989-308X
Yuji YamanashiDivision of Genetics, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-3562-8343
Tokyo Medical University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fundamental difference between benign and malignant tumors lies in their invasive ability. It is believed that malignant conversion of benign tumor cells is induced by a tumor cell-intrinsic accumulation of driver gene mutations. Here, we found that disruption of the Significance: This study uncovers tumor cell-extrinsic cues that can induce malignant conversion of benign tumors without intensifying mutagenesis in tumors, a novel concept potentially providing a new therapeutic target in malignancy.

Indexed as

Cell Transformation, NeoplasticNeoplasms, Glandular and EpithelialAnimalsCD8-Positive T-LymphocytesIntestinesMiceTumor Microenvironment

Identifiers

PMID36970719
PMCPMC10035524
OpenAlexW4312067737

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read49
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.